Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fournier, P.
Right arrow Articles by Clézardin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fournier, P.
Right arrow Articles by Clézardin, P.
[Cancer Research 62, 6538-6544, November 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats1

Pierrick Fournier2, Sandrine Boissier2, Stéphanie Filleur, Julien Guglielmi, Florence Cabon, Marc Colombel and Philippe Clézardin3

Institut National de la Santé et de la Recherche Médicale, Research Unit 403, Faculty of Medicine Laënnec, Lyon 69372 [P. F., S. B., J. G., M. C., P. C.], and Centre National de la Recherche Scientifique, UPR 9079, Villejuif 94801 [S. F., F. C.] France

Bisphosphonates (BPs) are used currently in the treatment of patients with bone metastases because these compounds inhibit bone resorption. We examined here the effects of BPs on inhibition of endothelial cell functions in vitro and in vivo. Treatment of endothelial cells with BPs (clodronate, risedronate, ibandronate, and zoledronic acid) reduced proliferation, induced apoptosis, and decreased capillary-like tube formation in vitro. Quantification of blood vessels in bone biopsy specimens from patients with Paget’s disease before and after clodronate treatment showed a 40% reduction of the vascularization after BP treatment. However, such a decreased vascularity could be secondary to a reduction of bone resorption. Therefore, the tissue distribution of [14C]BPs in male rats was examined to develop an angiogenesis model in a noncalcified tissue where BPs could accumulate. [14C]BPs (zoledronic acid, ibandronate, and clodronate) not only accumulated in bone but also transiently accumulated in the prostate. The effects of BPs on testosterone-induced revascularization of the prostate gland in castrated rats were then studied. Testosterone in combination with ibandronate or zoledronic acid induced a 17–35% reduction of the prostate weight compared with castrated rats treated with testosterone alone. Blood vessel immunostaining on prostate tissue sections revealed that both ibandronate and zoledronic acid induced a 50% reduction of the revascularization of the prostate gland. Moreover, zoledronic acid did not alter testosterone-induced activity of a luciferase gene reporter construct transfected in androgen-dependent prostatic cells, indicating that this BP did not directly interfere with testosterone. In conclusion, BPs have in vivo antiangiogenic properties, which could be of relevance to improve therapy and prevention of bone metastasis. In addition, our results extend the potential clinical use of BPs to patients with early prostate cancer.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
T. TANAKA, H. KAWASHIMA, K. OHNISHI, K. MATSUMURA, R. YOSHIMURA, M. MATSUYAMA, K. KURATSUKURI, and T. NAKATANI
Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells
Anticancer Res, April 1, 2009; 29(4): 1089 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 J Dent EducHome page
A. Mariotti
Bisphosphonates and Osteonecrosis of the Jaws
J Dent Educ., August 1, 2008; 72(8): 919 - 929.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. L. Estilo, C. H. Van Poznak, T. Wiliams, G. C. Bohle, P. T. Lwin, Q. Zhou, E. R. Riedel, D. L. Carlson, H. Schoder, A. Farooki, et al.
Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
Oncologist, August 1, 2008; 13(8): 911 - 920.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
I. R. Reid
Pathogenesis of Osteonecrosis of the Jaw
IBMS BoneKEy, February 1, 2008; 5(2): 69 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
V. M. Cartsos, S. Zhu, and A. I. Zavras
Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A medical claims study of 714,217 people
J Am Dent Assoc, January 1, 2008; 139(1): 23 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
J. T. Grbic, R. Landesberg, S.-Q. Lin, P. Mesenbrink, I. R. Reid, P.-C. Leung, N. Casas, C. P. Recknor, Y. Hua, P. D. Delmas, et al.
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
J Am Dent Assoc, January 1, 2008; 139(1): 32 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Scavelli, G. Di Pietro, T. Cirulli, M. Coluccia, A. Boccarelli, T. Giannini, G. Mangialardi, R. Bertieri, A. M. L. Coluccia, D. Ribatti, et al.
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma
Mol. Cancer Ther., December 1, 2007; 6(12): 3256 - 3262.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
D.B. Kimmel
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
Journal of Dental Research, November 1, 2007; 86(11): 1022 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Santini, B. Vincenzi, S. Galluzzo, F. Battistoni, L. Rocci, O. Venditti, G. Schiavon, S. Angeletti, F. Uzzalli, M. Caraglia, et al.
Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients
Clin. Cancer Res., August 1, 2007; 13(15): 4482 - 4486.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
M. C. Adornato, I. Morcos, and J. Rozanski
The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors
J Am Dent Assoc, July 1, 2007; 138(7): 971 - 977.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
P.M. Phal, R.W.T. Myall, L.A. Assael, and J.L. Weissman
Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws
AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1139 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
V. Kumar, B. Pass, S. A. Guttenberg, J. Ludlow, R. W. Emery, D. A. Tyndall, and R. J. Padilla
Bisphosphonate-related osteonecrosis of the jaws: A report of three cases demonstrating variability in outcomes and morbidity
J Am Dent Assoc, May 1, 2007; 138(5): 602 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. S. Yeh and J. R. Berenson
Treatment for myeloma bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6279s - 6284s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Vessella and E. Corey
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Sanna, L Preda, R Bruschini, M Cossu Rocca, S Ferretti, L Adamoli, E Verri, L Franceschelli, A Goldhirsch, and F Nole
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Ann. Onc., October 1, 2006; 17(10): 1512 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
A. Boyde
Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions
IBMS BoneKEy, September 1, 2006; 3(9): 19 - 23.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. H.G. Paterson
The Role of Bisphosphonates in Early Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 13 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
American Dental Association Council on Scientific
Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations.
J Am Dent Assoc, August 1, 2006; 137(8): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Wakchoure, M. A. Merrell, W. Aldrich, T. Millender-Swain, K. W. Harris, P. Triozzi, and K. S. Selander
Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo.
Clin. Cancer Res., May 1, 2006; 12(9): 2862 - 2868.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Yang, D. W. Burton, J. Geller, D. J. Hillegonds, R. H. Hastings, L. J. Deftos, and R. M. Hoffman
The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model
Clin. Cancer Res., April 15, 2006; 12(8): 2602 - 2606.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
R. L. Vessella, T. A. Guise, E. S. Susman, L. J. Suva, G. A. Clines, S. L. Kominsky, K. L. Weber, J. M. Chirgwin, L. K. McCauley, and W. Kozlow
Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA
IBMS BoneKEy, March 1, 2006; 3(3): 15 - 42.
[Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
C. A. MIGLIORATI, J. CASIGLIA, J. EPSTEIN, P. L. JACOBSEN, M. A. SIEGEL, and S.-B. WOO
Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper
J Am Dent Assoc, December 1, 2005; 136(12): 1658 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
M. D. MELO and G. OBEID
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition
J Am Dent Assoc, December 1, 2005; 136(12): 1675 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Guarneri, S. Donati, M. Nicolini, S. Giovannelli, R. D'Amico, and P. F. Conte
Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years
Oncologist, November 1, 2005; 10(10): 842 - 848.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G A Clines and T A Guise
Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-J. Kim, H. Uehara, S. Yazici, J. He, R. R. Langley, P. Mathew, D. Fan, and I. J. Fidler
Modulation of Bone Microenvironment with Zoledronate Enhances the Therapeutic Effects of STI571 and Paclitaxel against Experimental Bone Metastasis of Human Prostate Cancer
Cancer Res., May 1, 2005; 65(9): 3707 - 3715.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. A. Chabner
Late Toxicities of Drugs: Bisphosphonates
Oncologist, May 1, 2005; 10(5): 301 - 303.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. W. Hollingsworth, B. J. Chen, D. M. Brass, K. Berman, M. D. Gunn, D. N. Cook, and D. A. Schwartz
The Critical Role of Hematopoietic Cells in Lipopolysaccharide-induced Airway Inflammation
Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Hashimoto, K.-i. Morishige, K. Sawada, M. Tahara, R. Kawagishi, Y. Ikebuchi, M. Sakata, K. Tasaka, and Y. Murata
Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model
Cancer Res., January 15, 2005; 65(2): 540 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yuasa, M. Nogawa, S. Kimura, A. Yokota, K. Sato, H. Segawa, J. Kuroda, and T. Maekawa
A Third-Generation Bisphosphonate, Minodronic Acid (YM529), Augments the Interferon {alpha}/ss-Mediated Inhibition of Renal Cell Cancer Cell Growth Both In vitro and In vivo
Clin. Cancer Res., January 15, 2005; 11(2): 853 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S.-i. Yamagishi, R. Abe, Y. Inagaki, K. Nakamura, H. Sugawara, D. Inokuma, H. Nakamura, T. Shimizu, M. Takeuchi, A. Yoshimura, et al.
Minodronate, a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling
Am. J. Pathol., December 1, 2004; 165(6): 1865 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Green
Bisphosphonates: Preclinical Review
Oncologist, September 1, 2004; 9(suppl_4): 3 - 13.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. H. Bjarnason, A. S. Chan, S. M. Ott, S. L. Ruggiero, B. Mehrotra, H. G. Bone, and A. C. Santora
Ten Years of Alendronate Treatment for Osteoporosis in Postmenopausal Women
N. Engl. J. Med., July 8, 2004; 351(2): 190 - 192.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda
Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Peyruchaud, C.-M. Serre, R. NicAmhlaoibh, P. Fournier, and P. Clezardin
Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity
J. Biol. Chem., November 14, 2003; 278(46): 45826 - 45832.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Ruegg
Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death: EVIDENCE FOR THE SUPPRESSION OF SUSTAINED ACTIVATION OF FOCAL ADHESION KINASE AND PROTEIN KINASE B/Akt
J. Biol. Chem., October 31, 2003; 278(44): 43603 - 43614.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Ann. Onc., October 1, 2003; 14(10): 1468 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Santini, B. Vincenzi, G. Dicuonzo, G. Avvisati, C. Massacesi, F. Battistoni, M. Gavasci, L. Rocci, M. C. Tirindelli, V. Altomare, et al.
Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients
Clin. Cancer Res., August 1, 2003; 9(8): 2893 - 2897.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Santini, B. Vincenzi, G. Tonini, S. Scarpa, and A. Baldi
Correspondence Re: E. Corey et al., Zoledronic Acid Exhibits Inhibitory Effects on Osteoblastic and Osteolytic Metastases of Prostate Cancer. Clin. Cancer Res., 9: 295ndash;306, 2003.
Clin. Cancer Res., August 1, 2003; 9(8): 3215 - 3215.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. Vincenzi, D. Santini, L. Rocci, and G. Tonini
Bisphosphonates: new antiangiogenic molecules in cancer treatment?
Ann. Onc., May 1, 2003; 14(5): 806 - 807.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.